Pacira BioSciences (PCRX) Net Income towards Common Stockholders (2010 - 2026)

Pacira BioSciences has reported Net Income towards Common Stockholders for 17 years, with the latest figure at $4.7 million in Q2 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 196.0% year-over-year to $4.7 million in Q2 2026; TTM through Jun 2026 was $14.6 million, a 111.48% increase from a year earlier, with the FY2025 full-year figure at $7.0 million, up 107.07% from the prior year.
• Net Income towards Common Stockholders was $4.7 million for Q2 2026 at Pacira BioSciences, up from $2.9 million in the prior quarter.
• The five-year high for Net Income towards Common Stockholders was $25.8 million in Q2 2023, with the low at -$143.5 million in Q3 2024.
• Average Net Income towards Common Stockholders over 5 years is -$1.5 million, with a median of $5.1 million recorded in 2025.
• The sharpest annual moves came in 2023 and 2024: Net Income towards Common Stockholders jumped 1666.81% in 2023, then sank 1421.29% in 2024.
• Over 5 years, Net Income towards Common Stockholders stood at -$10.1 million in 2022, then jumped by 346.19% to $24.9 million in 2023, then tumbled by 35.5% to $16.0 million in 2024, then sank by 89.79% to $1.6 million in 2025, then soared by 184.24% to $4.7 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at $4.7 million (Q2 2026), $2.9 million (Q1 2026), and $1.6 million (Q4 2025), per Business Quant data.